secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001213900-23-039770
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix Q1 net loss $10.6M; DefenCath NDA resubmitted to FDA for 6-month review
--------------------------------------------------------------------------------

- Q1 net loss $10.6M ($0.24/share) vs $7.0M loss in Q1 2022; operating expenses $11.0M, up 57% YoY due to pre-launch activities.
- DefenCath NDA resubmitted to FDA; classified as Type 2 resubmission with 6-month review cycle, target action date November 2023.
- CMS proposed rule grants DefenCath NTAP up to $17,111 per hospital stay, contingent on FDA approval by July 1, 2024.
- US Patent Office issued notice of allowance for DefenCath composition, extending IP protection to 2042.
- Cash and short-term investments $55.6M; management believes sufficient to fund operations through first half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023039770/0001213900-23-039770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390023039770/ea178530-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-039770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer